Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Former Maryland Resident Sentenced For Congressional Office Harassment

Former Maryland resident sentenced to prison for making threatening calls to congressional offices, highlighting the seriousness of threats against elected...

Man sentenced to over 1 year in prison for thousands of harassing calls to congressional offices

Man sentenced to over 1 year in prison for thousands of harassing calls to congressional offices

A former Maryland resident has been sentenced to more than one year behind bars for making thousands of threatening and harassing telephone calls to dozens of congressional offices across the country

The Independent UK

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

International Business Times

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

inkl

Read news from The Economist, FT, and more,
with one subscription

Should You Buy These Stocks Before They Join The $1 Trillion Market Cap Club?

Should You Buy These Stocks Before They Join The $1 Trillion Market Cap Club?

Their strong fundamentals, brand strength, and drive to succeed could propel their stock higher.

Jim Cramer Names Six Companies That May Enter the Trillion-Dollar Stock Club

Jim Cramer Names Six Companies That May Enter the Trillion-Dollar Stock Club

In a recent episode of CNBC's Mad Money show, Jim Cramer named companies like Eli Lilly, Tesla, JPMorgan, and Walmart that could reach a $1 trillion market valuation.

International Business Times UK

NBCU to Offer First-Ever Commercial-Free Hour During Live Coverage of the Olympics Opening Ceremony

NBCU to Offer First-Ever Commercial-Free Hour During Live Coverage of the Olympics Opening Ceremony

The commercial-free hour, which begins at 1:30 p.m. ET on July 26, is sponsored by Coke, Delta, Eli Lilly, Toyota, Visa, and Xfinity

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Guardian - US

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

The Independent UK

A weight loss miracle! New shot does better than Ozempic and Wegovy during trials

A weight loss miracle! New shot does better than Ozempic and Wegovy during trials

Tirzepatide, which is sold under the brand names Mounjaro and Zepbound – which treat diabetes and weight loss, respectively – leads to more weight loss than semaglutide, new research has shown

The Independent UK

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

Get all your
news in one place.

100’s of premium titles.
One news app.

FDA Approves New Alzheimer's Drug To Slow Disease Progression

FDA approves Eli Lilly's donanemab for early Alzheimer's, offering hope for patients and caregivers. Treatment priced at 5 per vial.

The Guardian - US

FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

The Independent UK

FDA approves a second Alzheimer's drug that can modestly slow disease

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Weight loss drug could ease sleep apnoea in people with obesity, study says

Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder

The Independent UK

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

The World Health Organization and drugmaker Eli Lilly and Co. are warning patients to be wary of fake versions of weight-loss and diabetes medicines

The Independent UK

Alzheimer's drug that can slow disease gets backing from FDA advisers

Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia

Should a CFO switch industries? For these Fortune 500 finance chiefs, a new sector provided a career boost

Most CFOs have more options than they think, according to an expert.

Alphabet’s next CFO Anat Ashkenazi ‘fills a void’ for the company at key time during AI Revolution, says top analyst

Ashkenazi is a 23-year veteran of Eli Lilly and Company.

Google and Alphabet’s new CFO is Eli Lilly’s Anat Ashkenazi

Ashkenazi will have the task of investing in the company’s next wave of growth in the AI era.

1 'Strong Buy' Dividend Stock to Buy and Hold

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

People

John David Rainey

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Associated Press

United Airlines

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

326,376 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play